絞り込み

16404

広告

目標上積みの「タラノア対話」合意 (毎日新聞)

[PR] 温室ガス削減 「パリ協定」控え18年の1年間かけ実施へ 【ボン五十嵐和大】ドイツのボンで開催中の国連気候変動枠組み条約第23回締約国会議(COP23)...

  1. ドイツの温暖化会議で決議採択 - 福井新...
  2. 国内初の種類 恐竜の卵の化石を展示 山口...
  3. 温暖化、COP23大筋合意 先進国の削減...
  4. 本人望めば蘇生中止 消防庁委託研究班提言...

ニュース一覧

Early identification and intervention matters: A comprehensive review of current evidence and recommendations for the monitoring of bone health in patients with cancer.

著者 Brodowicz T , Hadji P , Niepel D , Diel I
Cancer Treat Rev.2017 Oct 18 ; 61():23-34.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (10view , 0users)

Full Text Sources

Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability. Biomarkers of bone turnover may also have a role in the early detection of bone metastases and can provide valuable prognostic information on disease progression. SREs can be delayed or prevented using agents such as the receptor activator of nuclear factor kappa B ligand (RANKL) inhibitor, denosumab, and bisphosphonates. Painful bone metastases can be treated with radiofrequency ablation, radiotherapy, or radionuclides such as radium-223 dichloride, which has been shown to delay the onset of SREs in men with castration-resistant prostate cancer. Close monitoring of bone health in patients with advanced cancer may lead to early identification of individuals with bone metastases who could benefit from early intervention to prevent SREs. This review examines current guideline recommendations for assessing and monitoring bone health in patients with advanced cancer, use of biomarkers and treatment of patients with bone metastases. The emerging evidence for the potential survival benefit conferred by early intervention with denosumab and bisphosphonates is also discussed, together with best practice recommendations.
PMID: 29100167 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード